RxDoctor Payments Data

Neiberg de Alcantara Lima, MD

Cardiology · Willimantic, CTNPI 1972098564

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Biotronik Inc. at 57.2% of the total. Reporting peaked in 2021 at $2,636 and has fallen 88.1% since, to $313 in 2025. Among cardiology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,330in general payments, 2019–2025

Across 109 payments — averaging $76.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$5K
  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$618
  • Medtronic$522
  • Boston Scientific$388
  • Sanofi-aventis U.S. LLC$177
  • plus $597 from 12 others

What the payments were for

  • Travel & lodging$3,60743%
  • Food & beverage$4,00148%
  • Education$7229%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,330 in reported general payments places this provider in the 90th percentile of 28 cardiology providers in Connecticut.

See all cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$22,355
Medicare patients
158
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan12$8,028

Paid to pharmacies, not to this prescriber.

Other cardiology in Willimantic

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →